Mitral valve annuloplasty double by the year 2030. Every year, 300,000 people worldwide undergo open heart surgery for mitral valve repair, 44,000 people in the US alone. Since it was initially established 40 years ago by Professor Alain Carpentier, mitral valve annuloplasty has been continuously improved and is considered the gold standard for the treatment of most etiologies of mitral valve dysfunction today. The goal of mitral valve annuloplasty is to regain mitral valve competence by restoring the physiological form and function of the normal mitral valve apparatus. Under normal conditions the mitral valve undergoes significant dynamic changes in shape and size throughout
Mitral insufficiency subsequent displacement of the papillary muscles and the dilatation of the mitral valve annulus. Rheumatic fever (RF) and Marfan's syndrome are other typical causes. Mitral valve stenosis (MVS) can sometimes be a cause of mitral regurgitation (MR) in the sense that a stenotic valve (calcified and with restricted range of movement) allows backflow (regurgitation) if it is too stiff and misshapen to close completely. Most MVS is caused by RF, so one can say that MVS is sometimes the proximal cause of MI/MR (that is, stenotic MI/MR) and that RF is often the distal cause of MVS, MI/MR, or both.